Cefprozil
File:Cefprozil.svg | |
Systematic (IUPAC) name | |
---|---|
7-[2-amino-2-(4-hydroxyphenyl)-acetyl]amino-8-oxo-3-prop-1-enyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
|
|
Clinical data | |
Trade names | Cefzil |
AHFS/Drugs.com | monograph |
MedlinePlus | a698022 |
Licence data | US FDA:link |
Pregnancy category |
|
Legal status |
|
Routes of administration |
Oral |
Pharmacokinetic data | |
Bioavailability | 95% |
Protein binding | 36% |
Biological half-life | 1.3 hours |
Identifiers | |
CAS Number | 92665-29-7 |
ATC code | J01DC10 (WHO) |
PubChem | CID: 9887643 |
DrugBank | DB01150 |
ChemSpider | 8063315 |
UNII | 1M698F4H4E |
KEGG | D07651 |
ChEBI | CHEBI:3506 |
ChEMBL | CHEMBL1742 |
Chemical data | |
Formula | C18H19N3O5S |
Molecular mass | 389.427 g/mol |
|
|
|
|
(what is this?) (verify) |
Cefprozil, sometimes spelled cefproxil and marketed under the trade name Cefzil,Cefproz.
Cefprozil is a second-generation cephalosporin type antibiotic. In Europe it is marketed using the trade names Procef and Cronocef.[citation needed] It can be used to treat bronchitis, ear infections, skin infections, and other bacterial infections.[citation needed] It comes as a tablet and as a liquid suspension.
Although there is a widely quoted cross-allergy risk of 10% between cephalosporins and penicillin, an article in the Journal of Family Practice[1] has shown no increased risk for cross-allergy for cefprozil and several other second-generation or later cephalosporins.
Contents
Spectrum of bacterial susceptibility and resistance
Currently bacteria like Enterobacter aerogenes, Morganella morganii and Pseudomonas aeruginosa are resistant to cefprozil, while Salmonella enterica serotype Agona and streptococci are susceptible to cefprozil. Some bacteria like Brucella abortus, Moraxella catarrhalis and Streptococcus pneumoniae have developed resistance towards cefprozil in varying degrees. Detailed minimum inhibition concentration information is given by the Cefprozil Susceptibility and Resistance Data sheet.[2]
Synthesis
Displacement of the allylic chloride in intermediate (1) with triphenylphosphine gives the phosphonium salt (2). This functionality is then converted to its ylide; condensation with acetaldehyde then leads to the vinyl derivative (3); deprotection then gives cefprozil. Semisynthetic oral cephalosporin consisting of ~90:10 Z/E isomeric mixture.
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references>
tag; parameter "group" is allowed only.
<references />
, or <references group="..." />
External links
- Cefprozil MedlinePlus Drug Information
<templatestyles src="Asbox/styles.css"></templatestyles>
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ H. Hoshi et al., DE 3402642; eidem, U.S. Patent 4,520,022 (1984, 1985 both to Bristol-Myers).
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ M. A. Kaplan et al., U.S. Patent 4,727,070 (1988 to Bristol-Myers).